Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New triple therapy aims to shrink lung tumors before surgery

NCT ID NCT07318636

Disease control Sponsor: The First Affiliated Hospital of Guangzhou Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new treatment for people with early-stage lung cancer that can be removed by surgery. The treatment combines NK cells (a type of immune cell), an immunotherapy drug (PD-1 antibody), and standard chemotherapy given before surgery. The main goals are to check safety and see how well the tumors respond. Only 10 participants will be enrolled.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able to understand and voluntarily sign the written informed consent form (ICF). * Male or female patients aged ≥18 years. * Histologically and/or cytologically confirmed resectable stage IB to IIIA non-small cell lung cancer (NSCLC) according to AJCC 8th edition. * Treatment-naïve NSCLC (no prior systemic anticancer therapy). * No sensitizing EGFR mutations (exon 19 deletion, exon 21 L858R) and no ALK gene rearrangement. * At least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. * Estimated life expectancy of more than 6 months. * Eastern Cooperative Oncology Group (ECOG) performance status 0-1. * Adequate bone marrow, liver, and renal function. * Female participants of childbearing potential must have a negative pregnancy test prior to initiation of study treatment. Exclusion Criteria: * Prior receipt of any systemic anticancer therapy. * Known sensitizing EGFR mutations or ALK gene rearrangements. * Active, known, or suspected autoimmune disease. * Interstitial lung disease. * Any medical condition, therapy, or laboratory abnormality that, in the opinion of the investigator, could confound the study results, interfere with the participant's ability to comply with study procedures, or is not in the best interest of the participant. * Locally advanced unresectable or metastatic NSCLC. * Major cardiovascular events, unstable arrhythmia, or unstable angina within 3 months prior to study treatment initiation. * Pregnant or breastfeeding women, or women of childbearing potential who are unwilling to use effective contraception during the study. * Any other condition judged by the investigator to make the participant unsuitable for clinical trial participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Resectable non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Resectable non-small cell lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.